Natural Polymorphisms in Human APOBEC3H and HIV-1 Vif Combine in Primary T Lymphocytes to Affect Viral G-to-A Mutation Levels and Infectivity

PLoS Genetics

Volumn 10, Issue 11, 2014, Pages

  Refsland, Eric W ^a,b,c,d   Hultquist, Judd F ^a,b,c,d   Luengas, Elizabeth M ^a,b,c,d   Ikeda, Terumasa ^a,b,c,d   Shaban, Nadine M ^a,b,c,d   Law, Emily K ^a,b,c,d   Brown, William L ^a,b,c,d   Reilly, Cavan ^b,e   Emerman, Michael ^f   Harris, Reuben S ^a,b,c,d  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

^f Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3D; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3F; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3H; HYDROLASE; UNCLASSIFIED DRUG; VIF PROTEIN; APOBEC3H PROTEIN, HUMAN; VIF PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1;

ALLELE; APOBEC3H GENE; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; GENE; GENE EXPRESSION; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIF GENE; CELL LINE; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MUTATION; PATHOGENICITY; PATHOLOGY; VIROLOGY; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

AMINOHYDROLASES; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; HAPLOTYPES; HIV INFECTIONS; HIV-1; HUMANS; MUTATION; POLYMORPHISM, GENETIC; VIF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VIRUS REPLICATION;

EID: 84912073468     PISSN: 15537390     EISSN: 15537404     Source Type: Journal    
DOI: 10.1371/journal.pgen.1004761     Document Type: Article

References (56)

1. Conticello SG, (2008) The AID/APOBEC family of nucleic acid mutators. Genome Biology 9: 229.
2. Refsland EW, Harris RS, (2013) The APOBEC3 family of retroelement restriction factors. Curr Top Microbiol Immunol 371: 1–27.
3. Desimmie BA, Delviks-Frankenberrry KA, Burdick RC, Qi D, Izumi T, et al. (2014) Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all. J Mol Biol 426: 1220–1245.
4. Malim MH, Bieniasz PD, (2012) HIV Restriction Factors and Mechanisms of Evasion. Cold Spring Harbor Perspectives in Medicine 2: a006940.
5. Jäger S, Kim DY, Hultquist JF, Shindo K, LaRue RS, et al. (2012) Vif hijacks CBF-beta to degrade APOBEC3G and promote HIV-1 infection. Nature 481: 371–375.
6. Zhang W, Du J, Evans SL, Yu Y, Yu XF, (2012) T-cell differentiation factor CBF-beta regulates HIV-1 Vif-mediated evasion of host restriction. Nature 481: 376–379.
7. Hultquist JF, Lengyel JA, Refsland EW, LaRue RS, Lackey L, et al. (2011) Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1. J Virol 85: 11220–11234.
8. Koning FA, Newman EN, Kim EY, Kunstman KJ, Wolinsky SM, et al. (2009) Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets. J Virol 83: 9474–9485.
9. Refsland EW, Stenglein MD, Shindo K, Albin JS, Brown WL, et al. (2010) Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction. Nucleic Acids Res 38: 4274–4284.
10. Janini M, Rogers M, Birx DR, McCutchan FE, (2001) Human immunodeficiency virus type 1 DNA sequences genetically damaged by hypermutation are often abundant in patient peripheral blood mononuclear cells and may be generated during near-simultaneous infection and activation of CD4(+) T cells. J Virol 75: 7973–7986.
11. Land AM, Ball TB, Luo M, Pilon R, Sandstrom P, et al. (2008) Human immunodeficiency virus (HIV) type 1 proviral hypermutation correlates with CD4 count in HIV-infected women from Kenya. J Virol 82: 8172–8182.
12. Vartanian JP, Meyerhans A, Sala M, Wain-Hobson S, (1994) G→A hypermutation of the human immunodeficiency virus type 1 genome: evidence for dCTP pool imbalance during reverse transcription. Proc Natl Acad Sci U S A 91: 3092–3096.
13. Albin JS, Harris RS, (2010) Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics. Expert Rev Mol Med 12: e4.
14. Caride E, Brindeiro RM, Kallas EG, de Sa CA, Eyer-Silva WA, et al. (2002) Sexual transmission of HIV-1 isolate showing G→A hypermutation. J Clin Virol 23: 179–189.
15. Fitzgibbon JE, Mazar S, Dubin DT, (1993) A new type of G→A hypermutation affecting human immunodeficiency virus. AIDS Res Hum Retroviruses 9: 833–838.
16. Gandhi SK, Siliciano JD, Bailey JR, Siliciano RF, Blankson JN, (2008) Role of APOBEC3G/F-mediated hypermutation in the control of human immunodeficiency virus type 1 in elite suppressors. J Virol 82: 3125–3130.
17. Kieffer TL, Kwon P, Nettles RE, Han Y, Ray SC, et al. (2005) G→A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo. J Virol 79: 1975–1980.
18. Kijak GH, Janini LM, Tovanabutra S, Sanders-Buell E, Arroyo MA, et al. (2008) Variable contexts and levels of hypermutation in HIV-1 proviral genomes recovered from primary peripheral blood mononuclear cells. Virology 376: 101–111.
19. Pace C, Keller J, Nolan D, James I, Gaudieri S, et al. (2006) Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation. J Virol 80: 9259–9269.
20. Piantadosi A, Humes D, Chohan B, McClelland RS, Overbaugh J, (2009) Analysis of the percentage of human immunodeficiency virus type 1 sequences that are hypermutated and markers of disease progression in a longitudinal cohort, including one individual with a partially defective Vif. J Virol 83: 7805–7814.
21. Suspène R, Rusniok C, Vartanian JP, Wain-Hobson S, (2006) Twin gradients in APOBEC3 edited HIV-1 DNA reflect the dynamics of lentiviral replication. Nucleic Acids Res 34: 4677–4684.
22. Ulenga NK, Sarr AD, Hamel D, Sankale JL, Mboup S, et al. (2008) The level of APOBEC3G (hA3G)-related G-to-A mutations does not correlate with viral load in HIV type 1-infected individuals. AIDS Res Hum Retroviruses 24: 1285–1290.
23. Wood N, Bhattacharya T, Keele BF, Giorgi E, Liu M, et al. (2009) HIV evolution in early infection: selection pressures, patterns of insertion and deletion, and the impact of APOBEC. PLoS Pathog 5: e1000414.
24. LaRue RS, Jonsson SR, Silverstein KA, Lajoie M, Bertrand D, et al. (2008) The artiodactyl APOBEC3 innate immune repertoire shows evidence for a multi-functional domain organization that existed in the ancestor of placental mammals. BMC Mol Biol 9: 104.
25. LaRue RS, Lengyel J, Jónsson SR, Andrésdóttir V, Harris RS, (2010) Lentiviral Vif degrades the APOBEC3Z3/APOBEC3H protein of its mammalian host and is capable of cross-species activity. J Virol 84: 8193–8201.
26. Zielonka J, Bravo IG, Marino D, Conrad E, Perkovic M, et al. (2009) Restriction of equine infectious anemia virus by equine APOBEC3 cytidine deaminases. J Virol 83: 7547–7559.
27. Zielonka J, Marino D, Hofmann H, Yuhki N, Lochelt M, et al. (2010) Vif of feline immunodeficiency virus from domestic cats protects against APOBEC3 restriction factors from many felids. J Virol 84: 7312–7324.
28. Virgen CA, Hatziioannou T, (2007) Antiretroviral activity and Vif sensitivity of rhesus macaque APOBEC3 proteins. J Virol 81: 13932–13937.
29. Schröfelbauer B, Chen D, Landau NR, (2004) A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif). Proc Natl Acad Sci U S A 101: 3927–3932.
30. Mariani R, Chen D, Schrofelbauer B, Navarro F, Konig R, et al. (2003) Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 114: 21–31.
31. Xu H, Svarovskaia ES, Barr R, Zhang Y, Khan MA, et al. (2004) A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion. Proc Natl Acad Sci U S A 101: 5652–5657.
32. Mangeat B, Turelli P, Liao S, Trono D, (2004) A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to Vif action. J Biol Chem 279: 14481–14483.
33. Bogerd HP, Doehle BP, Wiegand HL, Cullen BR, (2004) A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor. Proc Natl Acad Sci U S A 101: 3770–3774.
34. Li MM, Wu LI, Emerman M, (2010) The range of human APOBEC3H sensitivity to lentiviral Vif proteins. J Virol 84: 88–95.
35. OhAinle M, Kerns JA, Li MM, Malik HS, Emerman M, (2008) Antiretroelement activity of APOBEC3H was lost twice in recent human evolution. Cell Host Microbe 4: 249–259.
36. Wang X, Abudu A, Son S, Dang Y, Venta PJ, et al. (2011) Analysis of human APOBEC3H haplotypes and anti-human immunodeficiency virus type 1 activity. J Virol 85: 3142–3152.
37. Duggal NK, Fu W, Akey JM, Emerman M, (2013) Identification and antiviral activity of common polymorphisms in the APOBEC3 locus in human populations. Virology 443: 329–337.
38. Dang Y, Siew LM, Wang X, Han Y, Lampen R, et al. (2008) Human cytidine deaminase APOBEC3H restricts HIV-1 replication. J Biol Chem 283: 11606–11614.
39. Ooms M, Brayton B, Letko M, Maio SM, Pilcher CD, et al. (2013) HIV-1 Vif adaptation to human APOBEC3H haplotypes. Cell Host Microbe 14: 411–421.
40. OhAinle M, Kerns JA, Malik HS, Emerman M, (2006) Adaptive evolution and antiviral activity of the conserved mammalian cytidine deaminase APOBEC3H. Journal of virology 80: 3853–3862.
41. Binka M, Ooms M, Steward M, Simon V, (2012) The activity spectrum of Vif from multiple HIV-1 subtypes against APOBEC3G, APOBEC3F, and APOBEC3H. J Virol 86: 49–59.
42. Ooms M, Letko M, Binka M, Simon V, (2013) The resistance of human APOBEC3H to HIV-1 NL4-3 molecular clone is determined by a single amino acid in Vif. PLoS One 8: e57744.
43. Harris RS, Hultquist JF, Evans DT, (2012) The restriction factors of human immunodeficiency virus. J Biol Chem 287: 40875–40883.
44. Duggal NK, Emerman M, (2012) Evolutionary conflicts between viruses and restriction factors shape immunity. Nat Rev Immunol 12: 687–695.
45. Suspène R, Henry M, Guillot S, Wain-Hobson S, Vartanian JP, (2005) Recovery of APOBEC3-edited human immunodeficiency virus G→A hypermutants by differential DNA denaturation PCR. J Gen Virol 86: 125–129.
46. Refsland EW, Hultquist JF, Harris RS, (2012) Endogenous Origins of HIV-1 G-to-A Hypermutation and Restriction in the Nonpermissive T Cell Line CEM2n. PLoS Pathog 8: e1002800.
47. Harari A, Ooms M, Mulder LC, Simon V, (2009) Polymorphisms and splice variants influence the antiretroviral activity of human APOBEC3H. J Virol 83: 295–303.
48. Genomes Project C, Abecasis GR, Auton A, Brooks LD, DePristo MA, et al. (2012) An integrated map of genetic variation from 1,092 human genomes. Nature 491: 56–65.
49. Guo Y, Dong L, Qiu X, Wang Y, Zhang B, et al. (2014) Structural basis for hijacking CBF-beta and CUL5 E3 ligase complex by HIV-1 Vif. Nature 505: 229–233.
50. Schröfelbauer B, Senger T, Manning G, Landau NR, (2006) Mutational alteration of human immunodeficiency virus type 1 Vif allows for functional interaction with nonhuman primate APOBEC3G. J Virol 80: 5984–5991.
51. Russell RA, Pathak VK, (2007) Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F. J Virol 81: 8201–8210.
52. Chen KM, Harjes E, Gross PJ, Fahmy A, Lu Y, et al. (2008) Structure of the DNA deaminase domain of the HIV-1 restriction factor APOBEC3G. Nature 452: 116–119.
53. Harjes E, Gross PJ, Chen KM, Lu Y, Shindo K, et al. (2009) An extended structure of the APOBEC3G catalytic domain suggests a unique holoenzyme model. J Mol Biol 389: 819–832.
54. Albin JS, Haché G, Hultquist JF, Brown WL, Harris RS, (2010) Long-term restriction by APOBEC3F selects human immunodeficiency virus type 1 variants with restored Vif function. J Virol 84: 10209–10219.
55. Haché G, Shindo K, Albin JS, Harris RS, (2008) Evolution of HIV-1 isolates that use a novel Vif-independent mechanism to resist restriction by human APOBEC3G. Curr Biol 18: 819–824.
56. Gervaix A, West D, Leoni LM, Richman DD, Wong-Staal F, et al. (1997) A new reporter cell line to monitor HIV infection and drug susceptibility in vitro. Proc Natl Acad Sci U S A 94: 4653–4658.